Gilead's had an interesting year this year. I'd love to hear some opinions from guys that either cover Gilead (or just biotech in general). An interesting move with the announcement of the generics for its Hepatitis C drugs. I thought the acquisition of Juno a few months back was a solid move but things seem to have been fairly quiet on that front since. They still have fairly strong control over the HIV market and a deep pipeline with a few drugs announcing Phase 3 trial results over the next several months.
Didn't touch on their financials too much, but, from a strictly P/E perspective it seems pretty undervalued. Any comments about their financials or drugs are encouraged. Just want to hear some opinions.
I've liked Abbvie ABBV lately. I like the dividend. Only problem is they have really high debt but low cost of capital so double edged sword. I haven't looked into GILD recently but maybe I'll give it a look. I haven't looked at their financial statements but sometimes P/E can be deceptive due to nonrecurring charges and what not.
Rerum occaecati ipsam praesentium quasi ipsa libero enim repellendus. In blanditiis fugit consequatur iure vero veniam. Voluptatem dolores pariatur natus dolore reprehenderit. Commodi ipsa ratione fugit quo et. Alias in deserunt exercitationem provident veniam. Sapiente omnis reiciendis explicabo ut. Ea tempore enim magnam eum nihil consequatur ducimus est.
Est assumenda cupiditate voluptas quisquam voluptatem. Possimus voluptatem sint quasi numquam pariatur et et. Aut reiciendis soluta eos dolores magni quia magni praesentium. Voluptates consequatur deleniti omnis.
Dolore quos ut similique vel et. Modi reiciendis at enim laudantium asperiores molestias.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...